Navigation Links
Rigel Announces Second Quarter 2011 Financial Results
Date:8/2/2011

ing expenses

21,952

22,47942,812

48,090Income (loss) from operations

(21,557)

26,978(42,417)

4,628Interest income, net

83

51162

68Net income (loss)

$
(21,474)

$
27,029$ (42,255)

$   4,696Net income (loss) per share:Basic

$
(0.37)

$
.52$
(0.76)

$
.09Diluted

$
(0.37)

$
.51$
(0.76)

$
.09Weighted average shares used in computing net income (loss) per share:Basic

58,272

51,97455,290

51,969Diluted

58,272

52,51155,290

52,480Note AStock-based compensation expense included in:Research and development

$
2,337

$
,917$
4,850

$   5,000General and administrative

863

1,7842,187

3,868$
3,200

$
3,701$
7,037

$   8,868SUMMARY BALANCE SHEET DATA(in thousands)June 30,December 31,20112010(1) (unaudited) Cash, cash equivalents and availablefor sale securities

$
279,097

$
77,295Total assets

289,867

186,695Stockholders' equity

272,685

166,131(1)

Derived from audited financial statements 
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Rigel Earns Milestone Payments From AstraZeneca
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Wright, Co-Chair of the Alliance for Biosecurity and ... before the House Labor, Health and Human Services, ... of developing drugs, vaccines and other medical countermeasures ... catastrophic health emergencies. Effective medical countermeasures for many ...
... to Better Serve Asia-Pacific Clinical Trial Enrollment ConcernsNEWTON, ... leader in patient recruitment for clinical trials, has ... G.K., in Osaka, Japan. The company will be ... device companies, as well as CROs and SMOs, ...
... Sopherion Therapeutics, LLC, a biopharmaceutical company focused ... announced that it completed enrollment in its pivotal ... in metastatic HER-2-overexpressing breast cancer. This is ... product in combination with the current standard of ...
Cached Biology Technology:Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... greenhouse-gas emissions in comparison to fossil fuels. In the ... highlight a new study that factors in environmental costs ... short. The authors urge governments to be far more ... are more environmentally friendly than fossil fuels., Because fossil ...
... - The crystal structure of a molecule from a primitive ... more about the evolution of life from the simple to ... fungus protein bound to an RNA molecule, scientists from Purdue ... able to visualize how life progressed from an early self-replicating ...
... - Investigators at the University of Alabama at,Birmingham ... a,chemical ,messenger, leading to autoimmune disorders like rheumatoid,arthritis ... occurring chemical interleukin 17,(IL-17), an immunity protein. ... in autoimmune and,inflammatory responses, aside from its commonly ...
Cached Biology News:Scientists find missing evolutionary link using tiny fungus crystal 2Protein's new role discovered in autoimmune disease 2
... Gel/Mount is an aqueous-based mounting medium ... tissue sections. Gel/Mount is especially recommended ... allophycocyanin or FluoroBlue. It can also ... such as fluorescein (FITC), Rhodamine (TMRITC) ...
...
... Rabbit polyclonal to JNK1 (phospho T183 + ... an internal domain containing phosphorylated T183/Y185. Reactivity ... Rat. Not yet tested in other species. ... subgroups, including the ERK, JNK, and p38 kinases. ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: